(Reuters) -Metsera, an obesity drug developer, said on Friday that it has entered into an amended merger agreement with Pfizer, in which the New York-based company will acquire Metsera for up to $86.25 per share. Metsera's board has recommended that its shareholders "approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer." (Reporting by Rishabh Jaiswal in Bengaluru; Editing by Leslie Adler and Thomas Derpinghaus)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Mayabious Group won four metals, 1 Gold and 3 Bronze, at the Economic Times Award…
Nationwide participation sees civilians, armed forces and veterans run together from Kashmir to Kanyakumari and…
Interface of Katalon True Platform and Katalon AI Assistant. Source: Katalon Atlanta (Georgia) [USA], April…
New Delhi [India], April 09: If you’ve been hearing the name Nakli Yash Mehta repeatedly,…
New Delhi [India], April 09: At a time when political analysis is often reduced to…
New Delhi [India], April 09: The ET Now Business Conclave and Awards 2026 brought together…